Bilastine + Placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
72
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Allergic Conjunctivitis
Conditions
Allergic Conjunctivitis
Trial Timeline
Mar 26, 2021 โ Nov 30, 2022
NCT ID
NCT04810390About Bilastine + Placebo
Bilastine + Placebo is a phase 3 stage product being developed by Faes Farma for Allergic Conjunctivitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04810390. Target conditions include Allergic Conjunctivitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04810390 | Phase 3 | Completed |
| NCT00574210 | Phase 2 | Completed |
Competing Products
20 competing products in Allergic Conjunctivitis